1475-2891-7-17 1475-2891 Review <p>Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary</p> Messina J Mark markm@olympus.net Wood E Charles chwood@wfubmc.edu

Nutrition Matters, Inc, 439 Calhoun Street, Port Townsend, WA 98368, USA

Department of Pathology/Section on Comparative Medicine, Wake Forest University, School of Medicine, Winston-Salem, NC, USA

 Nutrition Journal 1475-2891 2008 7 1 17 http://www.nutritionj.com/content/7/1/17 18522734 10.1186/1475-2891-7-17 17 2 2008 03 6 2008 03 6 2008 2008 Messina and Wood; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

There has been considerable investigation of the potential for soyfoods to reduce risk of cancer, and in particular cancer of the breast. Most interest in this relationship is because soyfoods are essentially a unique dietary source of isoflavones, compounds which bind to estrogen receptors and exhibit weak estrogen-like effects under certain experimental conditions. In recent years the relationship between soyfoods and breast cancer has become controversial because of concerns – based mostly on in vitro and rodent data – that isoflavones may stimulate the growth of existing estrogen-sensitive breast tumors. This controversy carries considerable public health significance because of the increasing popularity of soyfoods and the commercial availability of isoflavone supplements. In this analysis and commentary we attempt to outline current concerns regarding the estrogen-like effects of isoflavones in the breast focusing primarily on the clinical trial data and place these concerns in the context of recent evidence regarding estrogen therapy use in postmenopausal women. Overall, there is little clinical evidence to suggest that isoflavones will increase breast cancer risk in healthy women or worsen the prognosis of breast cancer patients. Although relatively limited research has been conducted, and the clinical trials often involved small numbers of subjects, there is no evidence that isoflavone intake increases breast tissue density in pre- or postmenopausal women or increases breast cell proliferation in postmenopausal women with or without a history of breast cancer. The epidemiologic data are generally consistent with the clinical data, showing no indication of increased risk. Furthermore, these clinical and epidemiologic data are consistent with what appears to be a low overall breast cancer risk associated with pharmacologic unopposed estrogen exposure in postmenopausal women. While more research is required to definitively allay concerns, the existing data should provide some degree of assurance that isoflavone exposure at levels consistent with historical Asian soyfood intake does not result in adverse stimulatory effects on breast tissue.

Background

In 1990, participants of a workshop sponsored by the U.S. National Cancer Institute concluded that soybeans contain several putative chemopreventive agents 1. In the years since, there has been considerable investigation of the potential for soyfoods to reduce risk of cancer, and in particular cancer of the breast. The basis for the initial focus on breast cancer can be attributed to several things: the historically low breast cancer incidence rates in Asia, where soyfoods comprise an important dietary component 2; research demonstrating the potential for isoflavones – one of the putative chemopreventive agents identified in soybeans – to exert antiestrogenic effects 3; early epidemiologic data showing an inverse association between soy intake and breast cancer risk 4; and rodent studies showing a protective effect of soy intake against carcinogen-induced mammary cancer 5.

In recent years, however, the relationship between soyfoods and breast cancer has become controversial because of concerns that soy-derived isoflavones, which exhibit estrogen-like properties under certain experimental conditions, may stimulate the growth of existing estrogen-sensitive breast tumors 6. These concerns exist because of evidence showing that isoflavones bind and transactivate estrogen receptors (ERs) 78, induce proliferation and estrogenic markers in MCF-7 cells, an ER positive (ER+) breast cancer cell line 91011121314, and elicit estrogenic effects in rodent reproductive tissues 1516. In contrast to these findings, epidemiologic evidence shows that among Asian women, higher soy intake is associated with a nearly one-third reduction in breast cancer risk 17 and that Japanese breast cancer patients, in comparison to Western women, exhibit better survival rates even after controlling for stage of diagnosis 1819202122.

In 2006, the American Cancer Society concluded that breast cancer patients can safely consume up to three servings of traditional soyfoods per day, although the group advised against the use of more concentrated sources of isoflavones such as powders and supplements 23. Other expert views are less supportive of the use of any isoflavone-containing products for breast cancer survivors and in some cases for women at high risk of this disease 2425262728. Many women are understandably confused about whether to incorporate soy into their diet. Thus, there is a need for health professionals to have a better understanding of the current evidence relating to soy and breast cancer so that they can better advise their patients and clients. In this analysis and commentary we attempt to outline current concerns regarding estrogen-like effects of isoflavones in the breast and place these concerns in context of recent evidence regarding estrogen therapy (ET) use in postmenopausal women.

Background on isoflavones

The three soybean isoflavones are genistein, daidzein, and glycitein. These non-steroidal compounds are naturally present in the soybean and non-fermented soyfoods primarily in their beta glycoside forms: genistin, daidzin, and glycitin. Throughout this paper isoflavone amounts refer to the aglycone weight, which is ~60% of the glycoside. In the soybean itself and in most soy products, genistin/genistein, daidzin/daidzein, and glycitin/glycitein account for approximately 50–55%, 40–45%, and 5–10% of total isoflavone content, respectively 29. Older adults in Japan and Shanghai, China, typically consume between 25 and 50 mg/d isoflavones and probably no more than 5% of these populations consume ≥ 100 mg/d 30. In contrast, people in the United States and Europe consume on average < 3 mg/d of isoflavones 313233.

Isoflavones are diphenolic compounds with a chemical structure similar to estrogen that bind to both estrogen receptors alpha (ERα) and beta (ERβ) and, for this reason, are commonly referred to as phytoestrogens 3435. Isoflavones exhibit estrogen-like properties but bind more weakly to ERs than 17β-estradiol (E2), which is the primary physiologic estrogen. Genistein, which is the main circulating and best-studied isoflavone, transactivates ERα and induces estrogenic effects with ~103-104 less potency than E2 78. However, serum isoflavone concentrations after a high-soy meal can reach low micromolar levels 3637, thereby exceeding postmenopausal total estrogen concentrations by ~103 38. This evidence has contributed to the idea that isoflavones may potentially elicit estrogen-like effects and thus serve as a natural alternative to ET in postmenopausal women. Isoflavones also preferentially bind to and transactivate ERβ in comparison to ERα 93940 and induce distinct changes in ER conformation 41, leading to speculation that they may function as selective estrogen receptor modulators (SERMs) 424344. Despite this designation, unlike different forms of estrogen 4546474849505152535455, there is scant evidence for any clear estrogen-like or antiestrogenic-like effects of soyfood or isoflavone intake on the human breast or a number of other parameters 4455565758596061626364.

Effects of isoflavones on mammary/breast cell proliferation

Animal studies

Concern over the possible tumor-stimulatory effects of isoflavones is based largely on the proliferative effect of genistein on MCF-7 cells in vitro and in studies of mammary cancer in rodents. A variety of studies have shown that isoflavones stimulate ER+ human breast cancer cell xenoplants in ovariectomized athymic mice 1365666768, estrogen-dependent mammary tumors in rats 69, and reproductive tissues in adult female mice 7071. Other research using rodent models has also demonstrated that genistein is the primary isoflavone responsible for tumor stimulation 72; that more processed soy products result in faster tumor growth than less processed soy products 68; and that genistein inhibits the efficacy of tamoxifen, a SERM used in the treatment and prevention of breast cancer 73.

Even in rodent models, however, isoflavones are generally weak estrogen agonists relative to E2. Most rodent studies use scaled doses at least 5 times the amount found in traditional Asian diets 30, and many studies have used direct injection of purified isoflavones, which results in substantially higher levels of unconjugated isoflavones than dietary administration 70. Importantly, the isoflavone dose required for estrogen-like effects in women has yet to be identified despite three decades of study. So although isoflavones clearly act as estrogens in rodent models, relevant dose effects for human consumption are still very unclear.

There are several noteworthy limitations/weaknesses of the ovariectomized athymic mouse models used in many of the experiments noted above. First, the lack of immune function, which is a necessary element of these models, may eliminate a potential mechanism by which genistein reduces tumor development. Recent research in B6C3F1 mice shows that enhanced immune function resulting from pretreatment with genistein (20 ppm) is correlated with protection against chemically-induced mammary tumors 74. Second, unlike postmenopausal women, ovariectomized mice do not produce sufficient endogenous estrogen to promote development and growth of estrogen-dependent tumors. Thus, the effects of isoflavones are occurring in an estrogen-depleted environment that does not accurately reflect conditions in either premenopausal or postmenopausal women. It has been argued that estrogenic and tumor-stimulatory effects of isoflavones may be evident only in this type of hypoestrogenic environment. However, this criticism has been addressed by two different models in which isoflavones still lead to tumor stimulation. In one, mice are implanted with MCF-7Ca cells transfected with the enzyme aromatase, enabling the cells to synthesize estrogen; in the other model, mice are continually given small amounts of estrogen 75.

A third critique relates to isoflavone dose. In many studies showing estrogenic effects, mice are exposed to an amount of genistein (750 ppm) that greatly exceeds typical dietary intake. In Japan for example, adults consume about 15–20 mg genistein daily (total mean isoflavone intake is approximately 40 mg), which equates to a dietary concentration of about 30–40 ppm. When expressed on a caloric basis to adjust for differences in metabolism, the difference between human and rodent isoflavone exposure is ~8–16 times higher than the 25 – 50 mg per 1800 Kcal in a traditional Asian diet. (A 30 gm mouse consuming 3 gm of food/d with 750 ppm genistein will consume ~2.25 mg/d of isoflavones, which equates to ~405 mg per 1800 Kcal.) Exposure to purified genistein levels as low as 150 ppm has also been shown to stimulate MCF-7 cell growth, albeit to a lesser extent than higher genistein doses or E2 treatment 67. Fourth, it is not clear to what extent the existing MCF-7 xenoplants in nude mice reflect tumors in breast cancer patients. These tumors are fully transformed and composed of cells that are extremely sensitive to the growth-stimulating effects of estrogen. Finally, other potentially relevant rodent models 767778 have shown that isoflavones or isolated soy protein (ISP, by definition is >90% protein) suppress, rather than stimulate, the growth of tumors in mice implanted with MCF-7 cells and even enhance the efficacy of tamoxifen 7980.

Clinical studies

Breast tissue is highly regulated by sex hormones, particularly estrogens and progestogens, and breast epithelial proliferation is widely used as an indicator of hormonal exposure or effect. Epithelial cell proliferation also serves as an important prognostic marker in human breast cancer 81 and may help predict risk associated with different hormonal agents 82. A common method for evaluating proliferation is the immunohistochemical marker Ki67 (also called MIB1), which is a nuclear protein expressed by cells in all active phases of the cycle but not in quiescent or resting cells 83. Ki67 labeling correlates significantly with higher carcinoma grade, clinical response to endocrine therapy, higher risk of relapse, and worse survival in patients with early breast cancer 84858687.

Four trials, two involving breast cancer patients 8889, one in healthy subjects 61, and one in women undergoing breast biopsy or definitive surgery for breast cancer 90 were identified in which breast biopsies were taken before and after exposure to either isoflavone supplements or ISP (Table 1). In no case did the intervention lead to an increase in breast epithelial cell proliferation, which was used in these studies as a marker of potential tumor promotion. Daily isoflavone intake in these trials ranged from 36 6191 to >100 mg 8889 and study duration from 2 weeks 90 to one year 89. In comparison, postmenopausal ET results in modest variable increases in proliferation, while estrogen plus progestin therapy (EPT) results in more significant increases in breast cell proliferation 9293.

<p>Table 1</p>

Clinical effects of isoflavones and soy protein on markers of breast cancer risk

Author, Year/(Reference)

Subject No./Intervention Product/Isoflavone Exposure (mg/d)1

Study Length

Subject Description

Sampling Method

Primary Measures of Interest

Results

Breast Biopsies

Cheng, 2007/(61)

25/placebo

26/tablets/36

12 wk

Healthy postmenopausal women, age range, 49–69 y; mean age, ~57

Middle-needle biopsy of breast tissue using ultrasound to identify glandular tissue

ERα, ERβ, ERβcx,2 and PRα/β3 expression, Ki67

NSE5 for any measure. The proliferation marker, Ki67, was seen in 0% to 3% of samples, and no significant change was induced by isoflavone treatment.

Sartippour, 2004/(88)

26/historical controls

17/tablets/120

~22 d

Women with invasive/infiltrating breast cancer diagnosed by core-needle biopsy; mean age, ~61 y

Breast cancer biopsies and surgical specimens

ER & PR expression, p53, her-2/neu, DNA flow analysis, apoptosis and mitosis

NSE but trend toward an ↑ in the ratio of cells undergoing apoptosis versus mitosis in isoflavone (IF) group

Apoptosis/Mitosis*

Control

Isoflavone

Pre

6.5 ± 7.0

5.5 ± 4.7

Post

3.3 ± 3.4

5.8 ± 8.3

*Apoptosis and mitosis counts/high-power fields, means ± SD

Palomares, 2004/(89)

9/placebo

9/tablets/100

11.7 mo

Postmenopausal women previously diagnosed with in-situ or early stage invasive (Stage I-II) breast cancer; mean age, 56.9 ± 1.4 y

Ultrasound-guided 14-gauge core biopsies of the contralateral breast

Histology, ER/PR expression, Ki67

NSE for any measure.

Breast tissue histology*

Placebo

Isoflavone

Normal

5

5

Hyperplasia w/o atypia

2

2

Hyperplasia with atypia

0

1

Inadequate

2

1

Ki67 index* (mean)

5.9%

5.4%

(SD)

5.2%

6.5%

* values represent number of subjects

Hargreaves, 1999/(90)

53/UD5

28/UD + 60 g soy

protein/~45

14 d

Premenopausal women undergoing breast biopsy or definitive surgery for breast cancer;6 mean age, ~33 y

Grossly normal breast tissue (~1 cm3) excised at least 1 cm from the site of the lesion.

ER/PR expression, thymidine and Bcl-2 labeling, Ki67

NSE for any measure

Ki67 labeling index

Wks 1 & 2

Wks 3 & 4

Control

3.16 ± 3.08

6.03 ± 4.27

Soy

4.76 ± 6.16

6.17 ± 7.0

Values are mean ± SD

Mammograms (Breast Tissue Density)

Tice (in press)/(98)7

23/UD+25 g casein

24/UD+25 g ISP8/50

6 mo

Premenopausal women at high risk of breast cancer (defined by Gail risk ≥ 1.67% and mammographic breast density ≥ 50%)

Timed to late follicular phase (Day 10). Computer-aided contour method. Pre/post films read paired in random order at close of study, CC view and single reader

NSE

Powles, 2008/(99)

Premenopausal

111/tablets/409

111/Placebo/0

Postmenopausal

8/tablets/409

11/placebo/0

3 y

Healthy women aged between 35 and 70 y with at least one first-degree relative with breast cancer

Mammograms were conducted on both breasts. All film images were digitalized and breast density was determined from the digital or digitalized images. Breast density was measured on a scale of 0–100 with higher figures representing more dense breasts

Mean change (%) from baseline plus 95% CI Premenopausal

Isoflavone

3.03

(-5.53 – -0.54)

Placebo

6.60

(-9.04 – -4.16)

Postmenopausal

Isoflavone

-6.9

(-11.6 – -2.1)

Placebo

-8.0

(-15.7 – -0.2)

Maskarinec, 2004/(96)

103/UD

98/2 servings soyfoods/~50

~2.2 y

Healthy premenopausal women; average age, ~43 y

Computer-assisted density assessment. All mammograms for 1 woman were assessed during the same session, but the reader was unaware of the group status or the time sequence of the mammograms.

Breast tissue density (%)

Control

Soy

Baseline

48.1 ± 25.2

45.6 ± 23.3

Final

43.2 ± 24.3

40.5 ± 23.7

Change

4.1 ± 10.2

2.8 ± 9.6

Values are means ± SD. NSE

Atkinson, 2004/(97)

61/Placebo

56/tablets/43.59

12 mo

Postmenopausal women with Wolfe P2 or DY breast patterns; age range, 49–65 y; mean age, ~55

Percent densities assigned by drawing and measuring a cross on a 100 mm line (representing 0–100% density)

Reader 1: in the placebo and isoflavone groups respectively, 22% and 18% of women changed to a more lucent Wolfe pattern, 78% and 80% did not change, and 0% and 2% changed to a more dense Wolfe pattern. Reader 2: in the isoflavone and placebo groups, respectively, 15% and 19% of women changed to a more lucent Wolfe pattern, 84% and 80% did not change, and 1% and 1% changed to a more dense Wolfe pattern. NSE of isoflavone treatment

Maskarinec, 2003/(95)

15/UD

15/UD + tablets/76

~12 mo

Healthy premenopausal women; mean age, 42 y

Computer-assisted density assessment. Left and right cranio-caudal views of the mammograms (all free of malignancies) were scanned into a PC using a Cobrascan CX-612-T digitizer.

Percent breast tissue density

Control

Soy

Initial

49.5 ± 12.6

34.6 ± 18.8

Final

49.9 ± 12.8

37.1 ± 16.5

Values are means ± SD. NSE

Nipple Aspirate Fluid (NAF)

Qin, 2007/(103)

15/tablets/24

19/tablets/42

~1 mo

Premenopausal women with no history of atypia, in situ or invasive breast cancer; age range, 19–54; median, ~37 y

NAF was collected before and after one menstrual cycle. Samples from the left and right breast were kept separate

Estrogen marker, complement (C)3 and cell cytology

NSE

Hargreaves, 1999/(90)

53/UD

28/UD + 60 g soy

protein/~45

14 d

Premenopausal women undergoing breast biopsy or definitive surgery for breast cancer;6 mean age, ~33 y

NAF obtained by bimanual, four-quadrant compression of the breast. Fluid was collected into capillary tubes, and the volume of neat nipple secretion was calculated by multiplying the length (in millimeters) of nipple fluid in the tube by the cross-sectional area of the capillary tube lumen

Apolipoprotein D (apoD) and pS2 levels

Statistically significant ↑ and ↓ in pS2 and apoD levels, respectively (P ≤ 0.002).

Petrakis, 1996/(102)

24/UD + 37.4 g ISP/75

6 mo

Premenpausal (n = 14) and postmenopausal women (N = 10)

NAF was obtained with a Sartorius-type breast pump consisting of a 15-cc syringe attached to a small cup by a short piece of plastic tubing

NAF volume, gross cystic disease fluid protein (GCDFP-15) concentration, and NAF cytology.

Statistically significant ↑ in fluid volume and ↓ in GCDFP-15 in premenopausal women only. Epithelial hyperplasia in 7 of 24 women during and after ISP intake.

1 Daily isoflavone intake expressed as aglycone units; 2 ER, estrogen receptor; 3 PR, progesterone receptor; 4 NSE, no statistically significant effects; 5 UD, usual diet; 6Women diagnosed with benign breast disease included fibroadenoma (n = 38), reduction mammoplasty (n = 10), fibrocystic masses (n = 9), duct ectasia (n = 6), sclerosing adenosis (n = 3), lipoma (n = 1), and accessory breast removal (n = 1); thirteen cases of breast cancer were of the invasive ductal type, and 3 were ductal carcinoma in situ; fourteen patients were confirmed as taking oral contraceptives at the time of surgery, and 61 were parous; twenty (71.4%) patients completed 13–14 days of soy supplementation, 4 (14.3%) completed 10–12 days, and 4 (14.3%) completed 8–9 days of soy supplementation; however, all patients said they had taken the last soy tablet 24 h before surgery; 7 Details are described in reference; 8 ISP, isolated soy protein; 9 Isoflavones derived from red clover.

In one of the trials performed in healthy subjects, 28 postmenopausal women consumed 60 g textured vegetable (soy) protein containing 45 mg isoflavones for 2 weeks. No statistically significant effects on cell proliferation or several other estrogen-responsive markers were found, including progesterone receptor expression, Bcl-expression, and cells undergoing apoptosis and mitosis. However, levels of the estrogen-regulated protein pS2 significantly increased subsequent to soy consumption within breast nipple aspirate (NAF) 69. The second trial was a 12-week Swedish study in which 51 healthy postmenopausal women took a daily placebo or a supplement that provided 36 mg/d isoflavones 61. No statistically significant effects of isoflavone treatment were seen on cell proliferation or several other indicators of estrogenic effect (Table 1).

Two other pilot studies involving breast cancer patients also failed to find an effect of isoflavone supplements on breast cell proliferation. The intervention period averaged 23 days in one study 88 and a year in the other 89. In both studies subjects were exposed to ≥ 100 mg isoflavones per day; however, the one-year study included only 9 women per group and is published only as an abstract. Interestingly, in this study, biopsies taken from the contralateral breast revealed an increase in breast cell proliferation at baseline, which supports the idea that the "healthy" contralateral breast of breast cancer patients may be at an increased risk of developing a tumor 94.

In addition to the lack of effect on cell proliferation, none of the five studies conducted (three in premenopausal 95969798, one in postmenopausal women 97 and one involving both pre- and postmenopausal women 99) found that isoflavone exposure from soyfoods, ISP, or soybean- or red clover-derived supplements significantly affected breast tissue density (Table 1). Greater breast tissue density is associated with increased breast cancer risk and as was the case for cell proliferation, the lack of effects of isoflavones on breast tissue density generally contrasts with the effects of ET and EPT (see below) 100101.

Two additional clinical trials are worthy of comment (Table 1). In one, breast NAF was collected for a total of one year 102. Samples were taken over three months prior to soy exposure, then for 6 months during which women consumed 37.5 g ISP that provided 75 mg isoflavones daily, and then for 3 months after discontinuation of soy intake 102. Hyperplastic epithelial cells were noted in 7 of 24 (29.2%) women (4 premenopausal and 3 postmenopausal) while consuming soy whereas prior to soy consumption hyperplastic cells were noted in only 1 of 24 women (4.2%) 102. The authors concluded that these findings suggest that soybean isoflavones exert an estrogenic stimulus on breast tissue. However, it is important to point out that this was a pilot study with several limitations including the lack of a control group, a high dropout rate (only 15 of 37 subjects finished the 12-month regimen), and the fact that hyperplastic epithelial cells in the NAF persisted far beyond cessation of soy protein intake. Furthermore, a more recent study involving 34 premenopausal women found that isoflavones had no impact on breast cell cytology after one month exposure to either ~24 or 42 mg/d isoflavones 103. While the available trials examining breast proliferation and density have found no statistically significant effects of isoflavone-containing products it is important to recognize that many of these studies involved small sample sizes or were relative short in duration.

Finally, two epidemiologic studies were identified that examined the relationship between soy or isoflavone intake and breast cancer survival. The first found that soyfood intake was unrelated to survival over the 5.2 year follow-up period 104. In this study, approximately 63% of the 1001 Chinese breast cancer cases (out of 1459 subjects in the total cohort) for whom data on receptor status was available were ER+. In the other study, when comparing the fifth versus the first intake quintiles, isoflavone intake was associated with a reduced risk of all-cause mortality over the approximate 5-year follow-up period 105. Isoflavone intake was also associated with a marginal reduction in risk of breast cancer-specific mortality, although the effect was not statistically significant. Of note, the isoflavone intake cutoffs for the fifth quintile were only 7.48 and 0.60 mg/d for all-cause and breast cancer-specific mortality, respectively, and the percentage of ER+ patients among the 1210 subjects was not indicated.

Estrogen and breast cancer risk

Since the estrogen-like effects of isoflavones are at the core of the soy-breast cancer controversy, understanding the relationship between estrogen and breast cancer provides a potentially useful perspective. There is a large amount of evidence that endogenous estrogens are involved in the etiology of certain types of breast cancer 106107. Endogenous estrogens increase breast epithelial proliferation and may facilitate growth of estrogen-sensitive neoplastic or preneoplastic cells 108109. Many of the major epidemiologic risk factors for breast cancer also relate to endogenous estrogen exposure. For example, greater lifelong exposure to ovarian estrogen – as occurs with early menarche and late menopause – is associated with increased breast cancer risk 110111112, whereas oophorectomy reduces risk in premenopausal women 113114115. In postmenopausal women, higher endogenous circulating concentrations of estrogen 116117 are associated with increased risk, as are obesity and alcohol intake, both of which result in higher endogenous estrogen levels 112118. Conversely, treatment with tamoxifen and raloxifene, which inhibits ER activity in the breast, and aromatase inhibitors, which reduce endogenous estrogen production, are effective for treating and preventing ER+ breast cancer 119120.

The risk of breast cancer associated with exogenous estrogen exposure is less clear, however, due in part to recent results of the Women's Health Initiative (WHI). This study consisted of two large parallel randomized, double-blind, placebo-controlled clinical trials of hormone therapy designed to evaluate effects of conjugated equine estrogens (CEE) alone (for women with prior hysterectomy) or in combination with the progestin medroxyprogesterone acetate (MPA). In the WHI Estrogen + Progestin Trial, use of CEE + MPA led to a 26% increase in breast cancer risk (38 vs 30 cases per 10,000 person-years) which was highly significant in the weighted analysis (P < 0.001) 121. However, in the WHI Estrogen-Alone Trial, after an average of 7.1 years of follow-up, women assigned to CEE alone at 0.625 mg/d were 18% less likely to develop invasive breast cancer compared to women in the placebo group (26 vs 33 cases per 10,000 person-years; P = 0.09) 122. When the latter analysis was restricted to adherent subjects, risk in the CEE group was reduced by one-third (P = 0.03), while the incidence of localized breast carcinoma and ductal carcinoma were lower by 31% and 29%, respectively 123.

The reason for the marginal reduction in breast cancer risk associated with estrogen-alone therapy in the WHI trial is currently unknown. Prior epidemiologic evidence regarding ET effects on breast cancer risk is mixed but generally indicates either no significant effect or a modest increase in risk with long-term exposure 124125126127128. Variation within and across observational studies may relate to a variety of factors, including subject selection, screening frequency, duration of hormone use, hormone formulations and doses, and patient characteristics such as reproductive history, body mass index, and background endogenous estrogen context. Nevertheless, overall risks from observational studies are generally small for ET and notably lower than those reported for combined EPT, consistent with WHI results. Importantly, studies of ET use in breast cancer survivors (generally for periods < 5–10 years) also indicate minimal if any risk for recurrence or mortality 129130131132133134135.

Direct effects of ET (CEE in particular) on breast proliferation and density are generally modest and less than those seen with EPT. In one of the few clinical studies to assess breast proliferation following ET and EPT, postmenopausal women taking EPT but not ET had significantly greater breast epithelial Ki67 expression in terminal ductal lobular areas 82. In this study, ET was associated with modestly higher percent breast epithelial area (~15%) compared to the control group (~7%; P = 0.01), while EPT resulted in greater density beyond that seen with ET (~24%; P = 0.02 compared to ET).

Consistent with these findings, the Postmenopausal Estrogen/Progestin Interventions (PEPI) randomized placebo-controlled clinical trial reported a non-significant change in mammographic density of +1.2% after 1 year of CEE treatment compared to significant increases of +3.1 to +4.8% for different EPT regimens 136. In the WHI, absolute changes in mammographic density were not reported, although CEE resulted in a greater overall percentage of women with abnormal mammograms (36.2% for CEE compared to 28.1% for placebo) 123.

In conclusion, while there is general agreement that endogenous estrogen exposure has an important role in the etiology of breast cancer, the extent to which postmenopausal exogenous estrogen exposure affects risk is much less certain. Current evidence suggests that use of oral ET (particularly CEE) by relatively healthy postmenopausal women for periods < 10 years has very low if any risk for breast cancer and minimal to no effect on breast cancer recurrence or mortality in breast cancer survivors. This information provides a sensible context for considering the potential adverse effects on dietary soyfoods or isoflavones. Given the low overall risk associated with pharmacologic estrogen exposure, how reasonable is it to expect that any weak estrogen-like effects of soy-derived isoflavones (which have yet to be clearly demonstrated in the breast) may increase breast cancer risk or worsen the prognosis of breast cancer patients?

Summary and conclusion

Isoflavones are phytoestrogens which interact with ERs and generally function as weak estrogens in rodent and cell culture models. These estrogen-like effects have raised concern regarding soy/isoflavone consumption, particularly in the case of postmenopausal women at high risk for breast cancer. Currently there is little evidence to suggest that any potential weak estrogenic effects of dietary isoflavones have a clinically relevant impact on breast tissue in healthy women. Limited data suggest this is also the case for breast cancer survivors. This evidence includes multiple trials showing no effects on breast proliferation or mammographic density and considerable epidemiologic data showing either no effect or a modest protective role of soy/isoflavone intake on breast cancer risk. Tangential support for this idea is also provided by recent clinical trial findings regarding exogenous ET (in the form of CEE) showing a marginal decrease in risk of invasive breast cancer. Based on this evidence it seems unlikely that isoflavone consumption at dietary levels (i.e. <100 mg/day) elicits adverse breast cancer-promoting effects in healthy women or breast cancer survivors not undergoing active treatment. Findings from one rodent study showed that genistein may interfere with concurrent tamoxifen treatment, suggesting that breast cancer patients taking a SERM may need to limit soyfood intake and avoid isoflavone supplements. Currently there are no data to support the idea that soyfoods or isoflavone supplements improve the prognosis of breast cancer patients. Available data for ET effects on breast cancer recurrence and mortality provide some assurance for breast cancer patients that soyfoods/isoflavone supplements, when taken at dietary levels, do not contribute to recurrence rates although more data are clearly needed to better address this issue.

Abbreviations

CEE: conjugated equine estrogens; E2: 17β-estradiol; ER: estrogen receptor; ER+: estrogen receptor positive; ET: estrogen therapy; EPT: estrogen plus progestin therapy; ISP: isolated soy protein; MPA: medroxyprogesterone acetate; NAF: nipple aspirate fluid; NSE: no statistically significant effect; SERM: selective estrogen receptor modulator; WHI: Women's Health Initiative.

Competing interests

M.M. is president of Nutrition Matters, Inc., a nutrition consulting company with clients involved in the manufacture and/or sale of soyfoods and isoflavone supplements.

Authors' contributions

MM and CEW were equally involved in the writing of this manuscript.

 <p>The role of soy products in reducing risk of cancer</p> Messina M Barnes S J Natl Cancer Inst 1991 83 541 546 10.1093/jnci/83.8.541 1672382 <p>Estimates of the world-wide prevalence of cancer for 25 sites in the adult population</p> Pisani P Bray F Parkin DM Int J Cancer 2002 97 72 81 10.1002/ijc.1571 11774246 <p>The interaction in the immature mouse of potent oestrogens with coumestrol, genistein and other utero-vaginotrophic compounds of low potency</p> Folman Y Pope GS J Endocrinol 1966 34 215 225 5901836 <p>Dietary effects on breast-cancer risk in Singapore</p> Lee HP Gourley L Duffy SW Esteve J Lee J Day NE Lancet 1991 337 1197 2000 10.1016/0140-6736(91)92867-2 1673746 <p>Soybeans inhibit mammary tumors in models of breast cancer</p> Barnes S Grubbs C Setchell KD Carlson J Prog Clin Biol Res 1990 347: 239 253 2217394 <p>Soy for breast cancer survivors: a critical review of the literature</p> Messina MJ Loprinzi CL J Nutr 2001 131 3095S 108S 11694655 <p>Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta</p> Muthyala RS Ju YH Sheng S Williams LD Doerge DR Katzenellenbogen BS Helferich WG Katzenellenbogen JA Bioorg Med Chem 2004 12 1559 1567 10.1016/j.bmc.2003.11.035 15018930 <p>Potential endocrine-modulating effects of various phytoestrogens in the diet</p> Jefferson WN Newbold RR Nutrition 2000 16 658 662 10.1016/S0899-9007(00)00306-3 10906588 <p>Estrogen Receptor beta -Selective Transcriptional Activity and Recruitment of Coregulators by Phytoestrogens</p> An J Tzagarakis-Foster C Scharschmidt TC Lomri N Leitman DC J Biol Chem 2001 276 17808 17814 10.1074/jbc.M100953200 11279159 <p>Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro</p> Fioravanti L Cappelletti V Miodini P Ronchi E Brivio M Di Fronzo G Cancer Lett 1998 130 143 152 10.1016/S0304-3835(98)00130-X 9751267 <p>The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function</p> Miodini P Fioravanti L Di Fronzo G Cappelletti V Br J Cancer 1999 80 1150 1155 10.1038/sj.bjc.6690479 10376965 <p>Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells</p> Le Bail JC Champavier Y Chulia AJ Habrioux G Life Sci 2000 66 1281 1291 10.1016/S0024-3205(00)00435-5 10755463 <p>Estrogenic effects of genistein on the growth of estrogen receptor- positive human breast cancer (MCF-7) cells in vitro and in vivo</p> Hsieh CY Santell RC Haslam SZ Helferich WG Cancer Res 1998 58 3833 3838 9731492 <p>Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro</p> Zava DT Duwe G Nutr Cancer 1997 27 31 40 8970179 <p>Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats</p> Santell RC Chang YC Nair MG Helferich WG J Nutr 1997 127 263 269 9039826 <p>Phytoestrogen actions in the breast and uterus</p> Wood CE Barnes S Cline JM Phytoestrogens and Health Champaign, IL, AOCS Press Gilani GS and Anderson JJB 2002 440 469 <p>Epidemiology of soy exposures and breast cancer risk</p> Wu AH Yu MC Tseng CC Pike MC Br J Cancer 2008 98 9 14 10.1038/sj.bjc.6604145 18182974 <p>Ethnic differences and factors related to breast cancer survival in Hawaii</p> Meng L Maskarinec G Wilkens L Int J Epidemiol 1997 26 1151 1158 10.1093/ije/26.6.1151 9447393 <p>Breast cancer in Japan and United States: epidemiology, hormone receptors, pathology, and survival</p> Yonemoto RH Arch Surg 1980 115 1056 1062 6251779 <p>Some international differences in treatment and survival in breast cancer</p> Morrison AS Lowe CR MacMahon B Ravnihar B Yuasa S Int J Cancer 1976 18 269 273 10.1002/ijc.2910180302 955744 <p>Long-term results of breast-conserving treatment for early-stage breast cancer in Japanese women from multicenter investigation</p> Ohsumi S Sakamoto G Takashima S Koyama H Shin E Suemasu K Nishi T Nakamura S Iino Y Iwase T Ikeda T Teramoto S Fukutomi T Komaki K Sano M Sugiyama K Miyoshi K Kamio T Ogita M Jpn J Clin Oncol 2003 33 61 67 10.1093/jjco/hyg014 12629055 <p>Results of breast conservation therapy from a single-institution community hospital in Hawaii with a predominantly Japanese population</p> Kanemori M Prygrocki M Int J Radiat Oncol Biol Phys 2005 62 193 197 10.1016/j.ijrobp.2004.08.054 15850921 <p>Nutrition and physical activity during and after cancer treatment: an american cancer society guide for informed choices</p> Doyle C Kushi LH Byers T Courneya KS Demark-Wahnefried W Grant B McTiernan A Rock CL Thompson C Gansler T Andrews KS CA Cancer J Clin 2006 56 323 353 17135691 <p>Position of the American Dietetic Association and Dietitians of Canada: women's health and nutrition</p> Affenito SG Kerstetter J J Am Diet Assoc 1999 99 738 751 10.1016/S0002-8223(99)00178-9 10361541 <p>Phytoestrogens and breast cancer in postmenopausal women: a case control study</p> Murkies A Dalais FS Briganti EM Burger HG Healy DL Wahlqvist ML Davis SR Menopause 2000 7 289 296 10993028 <p>The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society</p> Menopause 2000 7 215 229 10914614 <p>Safety issues of soy phytoestrogens in breast cancer patients</p> De Lemos M J Clin Oncol 2002 20 3040 1; discussion 3041-2 12089239 <p>Implications of phytoestrogen intake for breast cancer</p> Duffy C Perez K Partridge A CA Cancer J Clin 2007 57 260 277 17855484 <p>Isoflavones in retail and institutional soy foods</p> Murphy PA Song T Buseman G Barua K Beecher GR Trainer D Holden J J Agric Food Chem 1999 47 2697 2704 10.1021/jf981144o 10552547 <p>Estimated Asian adult soy protein and isoflavone intakes</p> Messina M Nagata C Wu AH Nutr Cancer 2006 55 1 12 10.1207/s15327914nc5501_1 16965235 <p>Isoflavone intake in four different European countries: the VENUS approach</p> van Erp-Baart MA Brants HA Kiely M Mulligan A Turrini A Sermoneta C Kilkkinen A Valsta LM Br J Nutr 2003 89 Suppl 1 S25 30 12725653 <p>Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women</p> van der Schouw YT Kreijkamp-Kaspers S Peeters PH Keinan-Boker L Rimm EB Grobbee DE Circulation 2005 111 465 471 10.1161/01.CIR.0000153814.87631.B0 15687135 <p>Intake of dietary phytoestrogens by Dutch women</p> Boker LK Van der Schouw YT De Kleijn MJ Jacques PF Grobbee DE Peeters PH J Nutr 2002 132 1319 1328 12042453 <p>Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta</p> Kuiper GG Carlsson B Grandien K Enmark E Haggblad J Nilsson S Gustafsson JA Endocrinology 1997 138 863 870 10.1210/en.138.3.863 9048584 <p>Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta</p> Kuiper GG Lemmen JG Carlsson B Corton JC Safe SH van der Saag PT van der Burg B Gustafsson JA Endocrinology 1998 139 4252 4263 10.1210/en.139.10.4252 9751507 <p>Blood isoflavone levels during intake of a controlled hospital diet</p> Takashima N Miyanaga N Komiya K More M Akaza H J Nutr Sci Vitaminol (Tokyo) 2004 50 246 252 15527065 <p>Concentrations of isoflavones in plasma and urine of post-menopausal women chronically ingesting high quantities of soy isoflavones</p> Mathey J Lamothe V Coxam V Potier M Sauvant P Pelissero CB J Pharm Biomed Anal 2006 41 957 965 10.1016/j.jpba.2006.01.051 16513315 <p>Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients</p> Pasqualini JR Chetrite G Blacker C Feinstein MC Delalonde L Talbi M Maloche C J Clin Endocrinol Metab 1996 81 1460 1464 10.1210/jc.81.4.1460 8636351 <p>Ligands Differentially Modulate the Protein Interactions of the Human Estrogen Receptors alpha and beta</p> Margeat E Bourdoncle A Margueron R Poujol N Cavailles V Royer C J Mol Biol 2003 326 77 92 10.1016/S0022-2836(02)01355-4 12547192 <p>Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element</p> Kostelac D Rechkemmer G Briviba K J Agric Food Chem 2003 51 7632 7635 10.1021/jf034427b 14664520 <p>Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist</p> Pike AC Brzozowski AM Hubbard RE Bonn T Thorsell AG Engstrom O Ljunggren J Gustafsson JA Carlquist M Embo J 1999 18 4608 4618 1171535 10469641 10.1093/emboj/18.17.4608 <p>Short-term effect of phytoestrogen-rich diet on postmenopausal women</p> Brzezinski A Adlercreutz H Shaoul R Rösler R Shmueli A Tanos V Schenker JG Menopause 1997 4 89 94 10.1097/00042192-199704020-00005 <p>The differential ability of the phytoestrogen genistein and of estradiol to induce uterine weight and proliferation in the rat is associated with a substance specific modulation of uterine gene expression</p> Diel P Geis RB Caldarelli A Schmidt S Leschowsky UL Voss A Vollmer G Mol Cell Endocrinol 2004 221 21 32 10.1016/j.mce.2004.04.006 15223129 <p>Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women</p> Yildiz MF Kumru S Godekmerdan A Kutlu S Int J Gynaecol Obstet 2005 90 128 133 10.1016/j.ijgo.2005.05.005 15970291 <p>Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women</p> Ho JY Chen MJ Sheu WH Yi YC Tsai AC Guu HF Ho ES Hum Reprod 2006 21 2715 2720 10.1093/humrep/del245 16807281 <p>Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial</p> Lakoski SG Brosnihan B Herrington DM Am Heart J 2005 150 907 911 10.1016/j.ahj.2004.11.025 16290959 <p>A comparative longitudinal study on sex hormone binding globulin capacity during estrogen replacement therapy</p> Helgason S Damber JE Damber MG von Schoultz B Selstam G Sodergard R Acta Obstet Gynecol Scand 1982 61 97 100 7113697 <p>Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels</p> Serin IS Ozcelik B Basbug M Aygen E Kula M Erez R Eur J Obstet Gynecol Reprod Biol 2001 99 222 225 10.1016/S0301-2115(01)00398-0 11788176 <p>A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women</p> Reid IR Eastell R Fogelman I Adachi JD Rosen A Netelenbos C Watts NB Seeman E Ciaccia AV Draper MW Arch Intern Med 2004 164 871 879 10.1001/archinte.164.8.871 15111373 <p>Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women</p> Shulman LP Am J Cardiol 2002 89 47E 54E; discussion 54E-55E 10.1016/S0002-9149(02)02413-X 12084405 <p>The effect of droloxifene and estrogen on thyroid function in postmenopausal women</p> Marqusee E Braverman LE Lawrence JE Carroll JS Seely EW J Clin Endocrinol Metab 2000 85 4407 4410 10.1210/jc.85.11.4407 11095487 <p>Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women</p> Abech DD Moratelli HB Leite SC Oliveira MC Gynecol Endocrinol 2005 21 223 226 10.1080/09513590500279717 16316844 <p>Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women</p> Davies GC Huster WJ Shen W Mitlak B Plouffe L Jr. Shah A Cohen FJ Menopause 1999 6 188 195 10486787 <p>Monitoring endometrial thickness during estrogen replacement therapy with vaginosonography</p> Meuwissen JH van Langen H Radiology 1992 183 284 1549688 <p>Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study</p> Kaari C Haidar MA Junior JM Nunes MG Quadros LG Kemp C Stavale JN Baracat EC Maturitas 2006 53 49 58 10.1016/j.maturitas.2005.02.009 16257151 <p>The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women</p> D'Anna R Baviera G Corrado F Cancellieri F Crisafulli A Squadrito F Acta Obstet Gynecol Scand 2005 84 474 477 10.1111/j.0001-6349.2005.00661.x 15842212 <p>Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women</p> Garrido A De la Maza MP Hirsch S Valladares L Maturitas 2006 54 270 276 10.1016/j.maturitas.2005.12.002 16414215 <p>Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women</p> Khaodhiar L Ricciotti HA Li L Pan W Schickel M Zhou J Blackburn GL Menopause 2008 15 125 32 18257146 <p>Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production</p> Hall WL Vafeiadou K Hallund J Bugel S Reimann M Koebnick C Zunft HJ Ferrari M Branca F Dadd T Talbot D Powell J Minihane AM Cassidy A Nilsson M Dahlman-Wright K Gustafsson JA Williams CM Am J Clin Nutr 2006 83 592 600 16522905 <p>Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women</p> Katz DL Evans MA Njike VY Hoxley ML Nawaz H Comerford BP Sarrel PM Climacteric 2007 10 500 507 10.1080/13697130701750123 18049943 <p>Isoflavone treatment for acute menopausal symptoms</p> Cheng G Wilczek B Warner M Gustafsson JA Landgren BM Menopause 2007 14 468 473 10.1097/GME.0b013e31802cc7d0 17290160 <p>Isoflavone supplements do not affect thyroid function in iodine-replete postmenopausal women</p> Bruce B Messina M Spiller GA J Med Food 2003 6 309 316 10.1089/109662003772519859 14977438 <p>Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial</p> Marini H Minutoli L Polito F Bitto A Altavilla D Atteritano M Gaudio A Mazzaferro S Frisina A Frisina N Lubrano C Bonaiuto M D'Anna R Cannata ML Corrado F Adamo EB Wilson S Squadrito F Ann Intern Med 2007 146 839 847 17577003 <p>Effects of genistein on the endometrium: ultrasonographic evaluation</p> Sammartino A Di Carlo C Mandato VD Bifulco G Di Stefano M Nappi C Gynecol Endocrinol 2003 17 45 49 10.1080/713603185 12724018 <p>Physiological Concentrations of Dietary Genistein Dose-Dependently Stimulate Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) Tumors Implanted in Athymic Nude Mice</p> Ju YH Allred CD Allred KF Karko KL Doerge DR Helferich WG J Nutr 2001 131 2957 2962 11694625 <p>Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein</p> Allred CD Ju YH Allred KF Chang J Helferich WG Carcinogenesis 2001 22 1667 1673 10.1093/carcin/22.10.1667 11577007 <p>Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner</p> Allred CD Allred KF Ju YH Virant SM Helferich WG Cancer Res 2001 61 5045 5050 11431339 <p>Soy processing influences growth of estrogen-dependent breast cancer tumors</p> Allred CD Allred KF Ju YH Goeppinger TS Doerge DR Helferich WG Carcinogenesis 2004 25 1649 1657 10.1093/carcin/bgh178 15131010 <p>Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats</p> Allred CD Allred KF Ju YH Clausen LM Doerge DR Schantz SL Korol DL Wallig MA Helferich WG Carcinogenesis 2004 25 211 218 10.1093/carcin/bgg198 14578162 <p>Estrogenicity of the isoflavone metabolite equol on reproductive and non-reproductive organs in mice</p> Selvaraj V Zakroczymski MA Naaz A Mukai M Ju YH Doerge DR Katzenellenbogen JA Helferich WG Cooke PS Biol Reprod 2004 71 966 972 10.1095/biolreprod.104.029512 15151933 <p>Effects of dietary isoflavone aglycones on the reproductive tract of male and female mice</p> Cline JM Franke AA Register TC Golden DL Adams MR Toxicol Pathol 2004 32 91 99 10.1080/01926230490265902 14713553 <p>Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice</p> Ju YH Fultz J Allred KF Doerge DR Helferich WG Carcinogenesis 2006 27 856 863 10.1093/carcin/bgi320 16399773 <p>Dietary Genistein Negates the Inhibitory Effect of Tamoxifen on Growth of Estrogen-dependent Human Breast Cancer (MCF-7) Cells Implanted in Athymic Mice</p> Ju YH Doerge DR Allred KF Allred CD Helferich WG Cancer Res 2002 62 2474 2477 11980635 <p>Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein</p> Guo TL Chi RP Hernandez DM Auttachoat W Zheng JF Carcinogenesis 2007 28 2560 2566 2239241 17916904 10.1093/carcin/bgm223 <p>Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations</p> Ju YH Allred KF Allred CD Helferich WG Carcinogenesis 2006 27 1292 1299 10.1093/carcin/bgi370 16537557 <p>Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components</p> Zhou JR Yu L Zhong Y Nassr RL Franke AA Gaston SM Blackburn GL Prostate 2002 53 143 153 10.1002/pros.10141 12242729 <p>Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice</p> Zhou JR Yu L Mai Z Blackburn GL Int J Cancer 2004 108 8 14 10.1002/ijc.11549 14618609 <p>Soy and experimental cancer: animal studies</p> Hawrylewicz EJ Zapata JJ Blair WH J Nutr 1995 125 698S 708S 7884554 <p>Soy Phytochemicals Synergistically Enhance the Preventive Effect of Tamoxifen on the Growth of Estrogen-Dependent Human Breast Carcinoma in Mice</p> Mai Z Blackburn GL Zhou JR Carcinogenesis 2007 28 1217 1223 10.1093/carcin/bgm004 17234721 <p>Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination</p> Gotoh T Yamada K Ito A Yin H Kataoka T Dohi K Jpn J Cancer Res 1998 89 487 495 9685851 <p>Proliferation marker Ki-67 in early breast cancer</p> Urruticoechea A Smith IE Dowsett M J Clin Oncol 2005 23 7212 7220 10.1200/JCO.2005.07.501 16192605 <p>Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast</p> Hofseth LJ Raafat AM Osuch JR Pathak DR Slomski CA Haslam SZ J Clin Endocrinol Metab 1999 84 4559 4565 10.1210/jc.84.12.4559 10599719 <p>The Ki-67 protein: from the known and the unknown</p> Scholzen T Gerdes J J Cell Physiol 2000 182 311 322 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 10653597 <p>Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients</p> de Azambuja E Cardoso F de Castro G Jr. Colozza M Mano MS Durbecq V Sotiriou C Larsimont D Piccart-Gebhart MJ Paesmans M Br J Cancer 2007 96 1504 1513 10.1038/sj.bjc.6603756 17453008 <p>Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody</p> Weidner N Moore DH 2nd Vartanian R Hum Pathol 1994 25 337 342 10.1016/0046-8177(94)90140-6 8163266 <p>Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients</p> Chang J Powles TJ Allred DC Ashley SE Makris A Gregory RK Osborne CK Dowsett M Clin Cancer Res 2000 6 616 621 10690547 <p>Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features</p> Veronese SM Gambacorta M Am J Clin Pathol 1991 95 30 34 1987749 <p>A pilot clinical study of short-term isoflavone supplements in breast cancer patients</p> Sartippour MR Rao JY Apple S Wu D Henning S Wang H Elashoff R Rubio R Heber D Brooks MN Nutr Cancer 2004 49 59 65 10.1207/s15327914nc4901_8 15456636 <p>Effect of soy isoflavones on breast proliferation in postmenopausal breast cancer survivors</p> Palomares MR Hopper L Goldstein L Lehman CD Storer BE Gralow JR Breast Cancer Res Treatment 2004 88 4002 <p>Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast</p> Hargreaves DF Potten CS Harding C Shaw LE Morton MS Roberts SA Howell A Bundred NJ J Clin Endocrinol Metab 1999 84 4017 4024 10.1210/jc.84.11.4017 10566643 <p>The safety and benefits of soybean isoflavones. A natural alternative to conventional hormone therapy?</p> Messina M Menopause 2007 14 958; author reply 958 9 10.1097/gme.0b013e31812e5258 17667149 <p>Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology</p> Conner P Skoog L Soderqvist G Climacteric 2001 4 7 12 10.1080/713605030 11379380 <p>Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology</p> Conner P Soderqvist G Skoog L Graser T Walter F Tani E Carlstrom K von Schoultz B Breast Cancer Res Treat 2003 78 159 165 10.1023/A:1022987618445 12725416 <p>Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk</p> Hemminki K Ji J Forsti A Cancer Res 2007 67 868 870 10.1158/0008-5472.CAN-06-3854 17283115 <p>Mammographic densities in a one-year isoflavone intervention</p> Maskarinec G Williams AE Carlin L Eur J Cancer Prev 2003 12 165 169 10.1097/00008469-200304000-00011 12671541 <p>Effects of a 2-year randomized soy intervention on sex hormone levels in premenopausal women</p> Maskarinec G Franke AA Williams AE Hebshi S Oshiro C Murphy S Stanczyk FZ Cancer Epidemiol Biomarkers Prev 2004 13 1736 1744 15533901 <p>Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial</p> Atkinson C Warren RM Sala E Dowsett M Dunning AM Healey CS Runswick S Day NE Bingham SA Breast Cancer Res 2004 6 R170 9 400670 15084240 10.1186/bcr773 <p>Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings</p> Messina M McCaskill-Stevens W Lampe JW J Natl Cancer Inst 2006 98 1275 1284 16985246 <p>Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer</p> Powles TJ Howell A Evans DG McCloskey EV Ashley S Greenhalgh R Menopause Int 2008 14 6 12 10.1258/mi.2007.007033 18380954 <p>Mammographic density as a marker of susceptibility to breast cancer: a hypothesis</p> Boyd NF Lockwood GA Martin LJ Byng JW Yaffe MJ Tritchler DL IARC Sci Publ 2001 154 163 169 11220655 <p>Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer</p> Boyd NF Martin LJ Li Q Sun L Chiarelli AM Hislop G Yaffe MJ Minkin S Cancer Epidemiol Biomarkers Prev 2006 15 961 966 10.1158/1055-9965.EPI-05-0762 16702377 <p>Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women</p> Petrakis NL Barnes S King EB Lowenstein J Wiencke J Lee MM Miike R Kirk M Coward L Cancer Epidemiol Biomarkers Prev 1996 5 785 794 8896889 <p>Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women.</p> Qin W Zhu W Shi H Hewett JE Ruhlen RL MacDonald RS Rottinghaus GE Chien YC Sauter ER Am Inst Cancer Res November 1/2 2007 <p>Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study</p> Boyapati SM Shu XO Ruan ZX Dai Q Cai Q Gao YT Zheng W Breast Cancer Res Treat 2005 92 11 17 10.1007/s10549-004-6019-9 15980986 <p>Dietary Flavonoid Intake and Breast Cancer Survival among Women on Long Island</p> Fink BN Steck SE Wolff MS Britton JA Kabat GC Gaudet MM Abrahamson PE Bell P Schroeder JC Teitelbaum SL Neugut AI Gammon MD Cancer Epidemiol Biomarkers Prev 2007 16 2285 2292 10.1158/1055-9965.EPI-07-0245 18006917 <p>Estrogen carcinogenesis in breast cancer</p> Yager JD Davidson NE N Engl J Med 2006 354 270 282 10.1056/NEJMra050776 16421368 <p>Estrogen and the risk of breast cancer</p> Clemons M Goss P N Engl J Med 2001 344 276 285 10.1056/NEJM200101253440407 11172156 <p>Tamoxifen versus aromatase inhibitors for breast cancer prevention</p> Yue W Wang JP Li Y Bocchinfuso WP Korach KS Devanesan PD Rogan E Cavalieri E Santen RJ Clin Cancer Res 2005 11 925s 30s 15701888 <p>Increased cell division as a cause of human cancer</p> Preston-Martin S Pike MC Ross RK Jones PA Henderson BE Cancer Res 1990 50 7415 7421 2174724 <p>Epidemiology of breast cancer</p> Key TJ Verkasalo PK Banks E Lancet Oncol 2001 2 133 140 10.1016/S1470-2045(00)00254-0 11902563 <p>The role of estrogen in the initiation of breast cancer</p> Russo J Russo IH J Steroid Biochem Mol Biol 2006 102 89 96 1832080 17113977 10.1016/j.jsbmb.2006.09.004 <p>Predicting risk of breast cancer in postmenopausal women by hormone receptor status</p> Chlebowski RT Anderson GL Lane DS Aragaki AK Rohan T Yasmeen S Sarto G Rosenberg CA Hubbell FA J Natl Cancer Inst 2007 99 1695 1705 10.1093/jnci/djm224 18000216 <p>Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2</p> Kauff ND Barakat RR J Clin Oncol 2007 25 2921 2927 10.1200/JCO.2007.11.3449 17617523 <p>Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers</p> Kramer JL Velazquez IA Chen BE Rosenberg PS Struewing JP Greene MH J Clin Oncol 2005 23 8629 8635 10.1200/JCO.2005.02.9199 16314625 <p>Epidemiologic analysis of breast and gynecologic cancers</p> Hulka BS Prog Clin Biol Res 1997 396 17 29 9108587 <p>Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk</p> Hankinson SE Eliassen AH J Steroid Biochem Mol Biol 2007 106 24 30 10.1016/j.jsbmb.2007.05.012 17719770 <p>Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies</p> Key T Appleby P Barnes I Reeves G J Natl Cancer Inst 2002 94 606 616 11959894 <p>Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer</p> Kendall A Folkerd EJ Dowsett M J Steroid Biochem Mol Biol 2007 103 99 109 10.1016/j.jsbmb.2006.07.011 17088056 <p>Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial</p> Vogel VG Costantino JP Wickerham DL Cronin WM Cecchini RS Atkins JN Bevers TB Fehrenbacher L Pajon ER Jr. Wade JL 3rd Robidoux A Margolese RG James J Lippman SM Runowicz CD Ganz PA Reis SE McCaskill-Stevens W Ford LG Jordan VC Wolmark N Jama 2006 295 2727 2741 10.1001/jama.295.23.joc60074 16754727 <p>A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer</p> Thurlimann B Keshaviah A Coates AS Mouridsen H Mauriac L Forbes JF Paridaens R Castiglione-Gertsch M Gelber RD Rabaglio M Smith I Wardley A Price KN Goldhirsch A N Engl J Med 2005 353 2747 2757 10.1056/NEJMoa052258 16382061 <p>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial</p> Writing Group for the Women's Health Initiative Investigators JAMA 2002 288 321 333 10.1001/jama.288.3.321 12117397 <p>Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial</p> Anderson GL Limacher M Assaf AR Bassford T Beresford SA Black H Bonds D Brunner R Brzyski R Caan B Chlebowski R Curb D Gass M Hays J Heiss G Hendrix S Howard BV Hsia J Hubbell A Jackson R Johnson KC Judd H Kotchen JM Kuller L LaCroix AZ Lane D Langer RD Lasser N Lewis CE Manson J Margolis K Ockene J O'Sullivan MJ Phillips L Prentice RL Ritenbaugh C Robbins J Rossouw JE Sarto G Stefanick ML Van Horn L Wactawski-Wende J Wallace R Wassertheil-Smoller S Jama 2004 291 1701 1712 10.1001/jama.291.14.1701 15082697 <p>Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy</p> Stefanick ML Anderson GL Margolis KL Hendrix SL Rodabough RJ Paskett ED Lane DS Hubbell FA Assaf AR Sarto GE Schenken RS Yasmeen S Lessin L Chlebowski RT Jama 2006 295 1647 1657 10.1001/jama.295.14.1647 16609086 <p>A comparative review of the risks and benefits of hormone replacement therapy regimens</p> Warren MP Am J Obstet Gynecol 2004 190 1141 1167 10.1016/j.ajog.2003.09.033 15118656 <p>Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin</p> Ross RK Paganini-Hill A Wan PC Pike MC J Natl Cancer Inst 2000 92 328 332 10.1093/jnci/92.4.328 10675382 <p>Estrogen-progestin replacement and risk of breast cancer</p> Schairer C Lubin J Troisi R Sturgeon S Brinton L Hoover R Jama 2000 284 691 694 10.1001/jama.284.6.691 10927819 <p>Relationship between long durations and different regimens of hormone therapy and risk of breast cancer</p> Li CI Malone KE Porter PL Weiss NS Tang MT Cushing-Haugen KL Daling JR Jama 2003 289 3254 3263 10.1001/jama.289.24.3254 12824206 <p>Unopposed estrogen therapy and the risk of invasive breast cancer</p> Chen WY Manson JE Hankinson SE Rosner B Holmes MD Willett WC Colditz GA Arch Intern Med 2006 166 1027 1032 10.1001/archinte.166.9.1027 16682578 <p>Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively</p> Vassilopoulou-Sellin R Asmar L Hortobagyi GN Klein MJ McNeese M Singletary SE Theriault RL J Clin Oncol 1999 17 1482 1487 10334534 <p>Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study</p> Vassilopoulou-Sellin R Cohen DS Hortobagyi GN Klein MJ McNeese M Singletary SE Smith TL Theriault RL Cancer 2002 95 1817 1826 10.1002/cncr.10913 12404273 <p>Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality</p> O'Meara ES Rossing MA Daling JR Elmore JG Barlow WE Weiss NS J Natl Cancer Inst 2001 93 754 761 10.1093/jnci/93.10.754 11353785 <p>Estrogen replacement therapy after breast cancer: a 12-year follow-up</p> Peters GN Fodera T Sabol J Jones S Euhus D Ann Surg Oncol 2001 8 828 832 10.1007/s10434-001-0828-4 11776498 <p>Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk</p> Col NF Hirota LK Orr RK Erban JK Wong JB Lau J J Clin Oncol 2001 19 2357 2363 11304788 <p>Hormone replacement therapy after cancers</p> Creasman WT Curr Opin Oncol 2005 17 493 499 16093802 <p>Breast cancer survival and hormone replacement therapy: a cohort analysis</p> DiSaia PJ Brewster WR Ziogas A Anton-Culver H Am J Clin Oncol 2000 23 541 545 10.1097/00000421-200012000-00001 11202792 <p>Postmenopausal hormone therapy and change in mammographic density</p> Greendale GA Reboussin BA Slone S Wasilauskas C Pike MC Ursin G J Natl Cancer Inst 2003 95 30 37 12509398